| AMD | Age-related Macular Degeneration |
| AAV | Adeno-Associated Virus |
| AAV2 | Adeno-Associated Virus Serotype 2 |
| BCs | Bipolar Cells |
| ChR2 | Channelrhodopsin-2 |
| ChRmine | Channelrhodopsin Mine |
| CNV | Choroidal Neovascularization |
| FDA | U.S. Food and Drug Administration |
| GA | Geographic Atrophy |
| GHCR | Gleobacter–Human Chimeric Rhodopsin |
| ILM | Inner Limiting Membrane |
| IVT | Intravitreal Injection |
| LED | Light-Emitting Diode |
| MCO1/MCO-010 | Multicharacteristic Opsin 1/010 |
| MNV | Macular Neovascularization |
| MW-opsin | Medium-Wavelength Cone Opsin |
| ONL | Outer Nuclear Layer |
| OPN4 | Melanopsin |
| PPV | Pars Plana Vitrectomy |
| PRs | Photoreceptors |
| RGCs | Retinal Ganglion Cells |
| Rho | Rhodopsin |
| RPE | Retinal Pigment Epithelium |
| RPD | Reticular Pseudodrusen |
| SC | Suprachoroidal Injection |
| SD-OCT | Spectral Domain Optical Coherence Tomography |
| SDD | Subretinal Drusenoid Deposits |
| SNAG-mGluR2 | Synthetic Opsin–Metabotropic Glutamate Receptor 2 Fusion Protein |
| SR | Subretinal Injection |
| VEGF | Vascular Endothelial Growth Factor |